RT Journal Article
SR Electronic
T1 Clinical Assessment of a Plasma AT(N) Panel for Alzheimer’s Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.06.24310938
DO 10.1101/2024.08.06.24310938
A1 Collier, Bradley B.
A1 Chappell, Matthew R.
A1 Brandon, Whitney C.
A1 Le, Tien
A1 Harris, Ayla B.
A1 Volpe, Joseph M.
A1 Martone, Robert
A1 Winslow, John W.
A1 Boles, Deborah
A1 Valcour, Andre
A1 Grant, Russell P.
YR 2024
UL http://medrxiv.org/content/early/2024/08/09/2024.08.06.24310938.abstract
AB Importance With the emergence of new therapeutics for treatment of Alzheimer’s disease, there is currently a critical need for sensitive and accurate blood-based tests to assist with the diagnosis and treatment of Alzheimer’s disease.Objective To determine the clinical validity of an analytically validated plasma panel for the assessment of Alzheimer’s disease.Design, Setting, and Participants This cross-sectional study measured biomarkers representative of the Alzheimer’s disease AT(N) framework in 200 plasma specimens acquired from the Australian Imaging, Biomarker & Lifestyle (AIBL) Study of Ageing. Specimens were obtained from amyloid PET negative subjects classified as cognitively unimpaired (n = 75) and amyloid PET positive subjects classified as having no cognitive impairment (n = 49), mild cognitive impairment (n = 26), or Alzheimer’s disease dementia (n = 50).Exposures Amyloid PET and plasma Aβ42/40, pTau181, and NfL.Main Outcomes and Measures To assess the utility of the plasma panel to assess onset and progression of Alzheimer’s disease with respect to amyloid PET results and cognitive impairment.Results A difference was observed for each assay with respect to amyloid status (p<0.0001). Receiver operating characteristic (ROC) analysis of clinical specimen results from validated assays produced an area-under-the-curve (AUC) of 0.941 for Aβ42/40, 0.847 for pTau181, and 0.666 for NfL (p < 0.0001 for all biomarkers). The sensitivity (96.0%) and specificity (86.7%) observed for Aβ42/40 measurements meets current recommendations for triage testing. In addition, plasma levels of pTau181 and NfL were also found to increase with worsening cognitive impairment.Conclusions and Relevance The clinical concordance with amyloid PET for each biomarker is consistent with the biological progression of the AD continuum. As such, the availability of this AT(N) panel will provide clinicians with a simple blood-based means to provide evidence of AD pathological changes and could help identify AD patients much faster, shorten the overall AD patient diagnostic journey, and enable earlier treatment interventions.Competing Interest StatementBBC, MRC, WCB, TL, ABH, JMV, RM, JWW, DB, AV, and RPG are employees of Labcorp and all participate in the employee stock purchase plan.Funding StatementThis study did not receive any external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committees of Austin Health, St Vincent's Health, Hollywood Private Hospital, and Edith Cowan University approved of the Australian Imaging, Biomarker & Lifestyle (AIBL) Study of Ageing from which clinical specimens were acquired. Additional clinical specimens were purchased from ProteoGenex (Inglewood, CA) which were collected under ethical regulations and in accordance all applicable (local and international) laws (https://www.proteogenex.com/about-us/ethics-policy/). In addition, samples were collected internally from subjects that self-reported as healthy. These samples were collected under an IRB approved protocol (WCG IRB protocol #520100174). In all cases, informed consent was obtained from subjects prior to specimen collection.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data discussed are contained within the manuscript or the supplemental information.A±amyloid status (positive or negative) based on PET imagingAβamyloid betaAβ40amyloid beta consisting of amino acid residues 1-40Aβ42amyloid beta consisting of amino acid residues 1-42Aβ42/40the ratio of Aβ42 to Aβ40AIBLAustralian Imaging, Biomarkers and Lifestyle (Study of Ageing)AUCarea-under-the-curveADAlzheimer’s diseaseADDAlzheimer’s disease dementiaAT(N)amyloid, tau, neurodegenerationCSFcerebrospinal fluidM/Smoderate or severe (with respect to MMSE scores)MMSEmini-mental state examinationNegl.negligible (with respect to MMSE scores)NfLneurofilament light chainPETpositron emission tomographypTau181microtubule-associated protein tau phosphorylated at threonine 181ROCreceiver operator characteristic